Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05270577
Other study ID # Popcorn
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 2022
Est. completion date December 2023

Study information

Verified date February 2022
Source Linkoeping University
Contact Bergthor Björnsson, MD, PhD
Phone +46703766890
Email bergthor.bjornsson@liu.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare prehabilitation with physical exercise, psychological support, nutritional support and smoke/alchol stop to "standard of care" before canceer surgery.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients, aged 18 or older, who have been evaluated as eligible for surgery for malignancy in the esophagus, rectum or liver (only metastases from colorectal cancer) will be evaluated for participation. Exclusion Criteria: - Surgery is scheduled in less than 12 weeks. - Paralytic or completely immobilized patient, condition making physical training impractical. - Cognitive disability making participation impossible. - Not speaking or understanding the Swedish language well enough to read and understand the informed consent form.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Prehabilitation
prehabilitation
Standard care
No intervention

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Linkoeping University

Outcome

Type Measure Description Time frame Safety issue
Primary 6 minute walk test (6mwt) 6 minute walk test (6mwt) 12 weeks
Secondary 30 s chair stand test 30 s chair stand test 12 weeks
Secondary Test of hand grip strength Test of hand grip strength 12 weeks
Secondary International Physical Activity Questionnaire International Physical Activity Questionnaire 12 weeks
Secondary Cardiopulmonary exercise test with ventilatory gas analysis Cardiopulmonary exercise test with ventilatory gas analysis making it possible to calculate VOmax as well as other established measures of cardiopulmonary function 12 weeks
Secondary The presence of malnutrition evaluated with the Global Leadership Initiative on Malnutrition (GLM) criteria The presence of malnutrition evaluated with the Global Leadership Initiative on Malnutrition (GLM) criteria 12 weeks
Secondary Appetite and eating behavior is evaluated with Eating Symptom Questionnaire (ESQ) Appetite and eating behavior is evaluated with Eating Symptom Questionnaire (ESQ) 12 weeks
Secondary Appetite and eating behavior is evaluated with Disease Related Appetite Questionnaire (DRAQ) Appetite and eating behavior is evaluated with Disease Related Appetite Questionnaire (DRAQ) 12 weeks
Secondary 4-week point prevalence of smoking abstinence (among baseline smokers) 4-week point prevalence of smoking abstinence (among baseline smokers), measured with Fagerstroms scale 12 weeks
Secondary Weekly alcohol consumption Weekly alcohol consumption as reported in standard units 12 weeks
Secondary Episodes of heavy drinking per month Episodes of heavy drinking per month as reported in standard units at a single occation 12 weeks
Secondary The most severe complication occurring The most severe complication occurring (according to the Clavien-Dindo scale) until 90 days after surgery 90d after surgery
Secondary Sum of all complications in each patient (comprehensive complication index, CCI) Sum of all complications in each patient (comprehensive complication index, CCI) occuring up to 90 days after surgery 90d after surgery
Secondary Length of hospitalization Length of hospitalization 90d after surgery
Secondary Time to functional recovery of physical status as compared to baseline values Defined as number of days after surgery until the patient has reached all of the following: being mobile at the preoperative level, having sufficient pain control with only oral or transdermal medication, being able to maintain food intake without intravenous fluids and not being in need of intravenous medications 90d after surgery
Secondary Clinical Frailty Scale Clinical Frailty Scale 12 weeks
Secondary Grade of sarcopenia Grade of sarcopenia 12 weeks
Secondary The frequency of failures to go through the full treatment program as planned at the first MDT (including, but not limited to, the full oncological chemotherapy program, radiation treatment and final surgery) The frequency of failures to go through the full treatment program as planned at the first MDT (including, but not limited to, the full oncological chemotherapy program, radiation treatment and final surgery) 90 days
Secondary Time from surgery until the day of first dose of adjuvant chemotherapy (among liver and rectal cancer patients for whom postoperative chemotherapy is planned) Time from surgery until the day of first dose of adjuvant chemotherapy (among liver and rectal cancer patients for whom postoperative chemotherapy is planned) 90 day after surgery
Secondary Proportion of patients not able to receive all treatment despite no dissemination of disease Proportion of patients not able to receive all treatment despite no dissemination of disease 90 day after surgery
Secondary Overall survival Overall survival 5 years
Secondary Quality of Life (QoL) Quality of Life (QoL) 2 years after surgery
Secondary Incremental cost-effectiveness ratio Incremental cost-effectiveness ratio, calculated as the median cost divided by the quality adjusted life years obtained until 2 years after surgery 2 years after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients